Skip to Content
DiagnosticsDiagnostics
  • Article
  • Open Access

21 November 2026

13 Pages

The Cerebrospinal Fluid Concentration of Amylin in Alzheimer’s Disease

,
,
,
,
,
and
1
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Waszyngtona 15A, 15-269 Bialystok, Poland
2
Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A, 15-269 Bialystok, Poland
3
Dementia Disorders Centre, Medical University of Wroclaw, 50-425 Ścinawa, Poland
4
Podlaskie Center for Psychogeriatrics, Swobodna 38, 15-756 Białystok, Poland
Diagnostics2026, 16(23), 3919;https://doi.org/10.3390/diagnostics16233919 
(registering DOI)
This article belongs to the Special Issue Biomarkers and Biodiagnostics in Neurodegenerative Diseases

Abstract

Background/Objectives: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid pathology, tau-related neurodegeneration, and cognitive decline. Increasing evidence suggests that metabolic dysfunction contributes to AD pathogenesis; however, the clinical significance of cerebrospinal fluid (CSF) amylin remains poorly understood. The aim of this study was to assess for the first time the potential relationship between metabolic dysfunction based on the changes in the CSF amylin and amyloid pathology as well as neurodegeneration in patients with AD. Methods: The study included 57 patients with AD and 21 cognitively unimpaired controls. CSF amylin concentrations were measured using immunoassay. The concentration of Aβ42, Aβ40, pTau181 and total tau were analyzed on Lumipulse G1200. Results: CSF amylin concentrations were significantly lower in patients with AD than in cognitively unimpaired controls. Amylin levels correlated positively with CSF Aβ42 and the Aβ42/Aβ40 ratio and negatively with total tau and phosphorylated tau 181. A significant positive correlation was also observed between CSF amylin concentration and Mini-Mental State Eamination (MMSE) score. Furthermore, CSF amylin concentrations were significantly lower in Aβ-positive than in Aβ-negative individuals. ROC analysis demonstrated good discrimination between patients with AD and controls (AUC = 0.858). Conclusions: Reduced CSF amylin concentrations are associated with amyloid pathology, tau-related neurodegeneration, and cognitive impairment in AD. These findings suggest for the first time that CSF amylin may represent a promising biomarker reflecting metabolic dysfunction associated with AD pathology which is very important not only for diagnosis but also for treatment of AD patients.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.